Not Signed In - Nuvelo And Bayer Healthcare Announce Phase 3 Trials Of Alfimeprase In Patients With Acute Peripheral Arterial Occlusion Did Not Meet Primary Endpoints
Mon, 25 Dec 2006 08:00 AM EST
... Nuvelo, Inc.(Nasdaq: NUVO) and Bayer HealthCare today announced top-line data demonstrating that the Phase 3 clinical trial of alfimeprase in acute peripheral arterial occlusion (PAO), known as NAPA-2 (Novel Arterial Perfusion with Alfimeprase-2), did not meet its primary endpoint of avoidance of open vascular surgery within 30 days of treatment. [click link for full article] ...
Related Topics
- Acute arterial occlusion - kidney
- Peripheral Neuropathy
- Pulmonary Hypertension
- Blood Gases
- Primary
- Peripheral arterial disease
- Primary Care
- Peripheral Vascular Disease
- Coronary Occlusion
- Vascular Disease
- Aspirin
- Clinical Trials
- Acute Care
- Neuropathy
- Histoplasmosis - acute (primary) pulmonary
- Peripheral Blood Stem Cells
- Peripheral Nerve Disorders
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Retinal artery occlusion
email this page
print this page
bookmark this page
feedback on this page
